OCT Devices for Eye Cancer

This trial aims to compare two devices used for optical coherence tomography (OCT), a scanning method that creates images of the back of the eye. These devices may help doctors better detect and monitor eye cancers. Participants will test the Heidelberg Spectralis OCT and the Intalight Dream OCT. This trial suits individuals with at least one eye tumor, either inside or on the surface, who can sit still for about two minutes. As an unphased trial, it offers a unique opportunity to advance eye cancer detection technology.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Previous studies have shown that both the Heidelberg Spectralis OCT and the Intalight Dream OCT are safe and easy to use for eye imaging. Research indicates that these devices are noninvasive, meaning they do not involve surgery or breaking the skin, which generally ensures patient safety.

For the Heidelberg Spectralis OCT, studies have confirmed its ability to consistently provide accurate results without causing harm. Similarly, the Intalight Dream OCT has received approval for use in the EU, indicating it meets safety standards there.

Researchers are excited about the OCT devices for eye cancer because they offer a non-invasive way to capture detailed images of ocular tumors. Unlike traditional methods that might rely on biopsies or less precise imaging, the Heidelberg Spectralis OCT and Intalight Dream OCT provide high-resolution scans that can help in assessing tumor size and progression without surgery. These devices are particularly promising because they allow for real-time monitoring, potentially leading to more personalized and timely treatment adjustments for patients.

This trial will evaluate the effectiveness of two OCT devices for detecting and monitoring eye cancers. Participants will be assessed using either the Heidelberg Spectralis OCT or the Intalight Dream OCT. Studies have shown that the Heidelberg Spectralis OCT provides detailed images, aiding doctors in identifying different types of eye tumors and improving visibility through cataracts. Meanwhile, the Intalight Dream OCT offers a wide view of the retina, which is crucial for locating eye tumors. Both devices have demonstrated manageable side effects, making them promising options for managing eye cancer.¹²³⁴⁵